The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy;Utilidad de la tizanidina. Seguimiento de un año en el tratamiento de la espasticidad en la parálisis cerebral infantil

Revista de Neurologia

Volumn 43, Issue 3, 2006, Pages 132-136

  Vásquez Briceño, Ascela ^a   Arellano Saldana M E ^a   Leon Hernandez S R ^a   Morales Osorio, M G ^a  

^a INSTITUTO NACIONAL DE REHABILITACIÓN   (Mexico)

Author keywords

Cerebral palsy; Children's spasticity; Tizanidine

Indexed keywords

PLACEBO; TIZANIDINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CENTRAL MUSCLE RELAXANT; CLONIDINE; DRUG DERIVATIVE;

ADOLESCENT; ARTICLE; ASHWORTH SCALE; BODY POSTURE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LIVER FUNCTION TEST; MALE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REFLEX; SPASTICITY; LONGITUDINAL STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; CLONIDINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; PROSPECTIVE STUDIES;

EID: 35348816259     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4303.2005414     Document Type: Article

References (20)

1. Davis DW. Review of cerebral palsy. Part I: description, incidence, and etiology. Neonatal Netw 1997; 16: 7-12.
2. Bottos M, Granato T, Alibrio G. Prevalence of cerebral palsy in northeast Italy from 1965 to 1989. Dev Med Child Neurol 1999; 41: 26-39.
3. Holmgrem J, Soza S. Enfermedades invalidantes de la infancia. Enfoque integral de rehabilitación. Santiago de Chile: Sociedad Pro Ayuda al Niño Lisiado; 1995.
4. García G, Magallanes C. Estudio epidemiológico de la parálisis cerebral infantil en el centro nacional de rehabilitació n. Rev Mex Med Fis Reh 1999; 11: 17-9.
5. Goldstein EM. Spasticity management, an overview. J Child Neurol 2001; 16: 16-23.
6. Bela S. Imidazoline antihypertensive drugs -a critical review on their mechanism of action. Pharmacol Ther 2002; 93: 1-35.
7. Shumilina AP, Guzeva VI, Skoromets AA. Sirdalud in the practice of the pediatric neurologist. Zh Nevrol Psikhiatr Im S S Korsakova 1997; 97: 45-6.
8. Maksimov O, Secheiko MV, Andriichuk EL. The use of sirdalud in the treatment of spasticity in infantile cerebral palsy. Zh Nevrol Psikhiatr Im S S Korsakova 1999; 99: 22-3.
9. Mariko K, Donald G. Drugs used to treat spasticity. Drugs 2000; 59: 487-95.
10. Lataste X, Davis Emre M. Comparative profile of tizanidine in the management of spasticity. Neurology 1994; 44: 53-9.
11. Brin IL, Kurenkov AL, Gotlib VI. The use of sirdalud in cerebral palsy in children. Zh Nevrol Psikhiatr Im S S Korsakova 1999; 99: 30-3.
12. Coward D. Tizanidine: neuropharmacology and mechanism of action. Neurology 1994; 44: 6-11.
13. Wallace J. Summary of combined clinical analysis of controlled trials with tizanidine. Neurology 1994; 44: 60-9.
14. De Graaf E, Oosterveld M, Tjabbes T. A case of tizanidine induced hepatic injury. J Hepatol 1996; 25: 772-3.
15. Wasgstaff A, Bryson HM. Tizanidine a review of its pharmacology clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drug 1997; 53: 435-52.
16. Gaebler-Spira D, Tata N, Gadi-Revivo DO. The use of tizanidine in a pediatric population: clinical outcome [abstract]. Arch Phys Med Rehabil 2001.
17. Burnet EC, Bodofsky EB. Tizanidine in the management of pediatric spasticity [abstract]. Am J Phys Med Rehabil 2001.
18. Barry MJ. Physical therapy interventions for patients with movement disorders due to cerebral palsy. J Child 1996; 11: 51-6.
19. Consensus Statements. Consensus conference on efficacy of physical therapy in the management of cerebral palsy. Pediatric Phys Ther 1990; 2: 175-6.
20. Helse P, McGee J, Graveline CH. Physical management of spasticity. J Child Neurol 2001; 16: 24-30.